1910, the only AI-native biotech pioneering small and large molecule therapeutics discovery, today announced the publication of PEGASUS (TM), a multimodal AI model that achieves state-of-the-art ...
OXFORD, England--(BUSINESS WIRE)--British techbio innovator Etcembly is coming out of stealth mode, kickstarting the next generation of immunotherapies with a pipeline of best-in-class T cell receptor ...
The engagement establishes a multi-phase framework to support AI enabled capital efficient development of Teverelix, a next generation GnRH antagonist, as a first in class market product for acute ...
Studying the cell is a difficult and time-consuming process, but scientists have pinpointed generative AI as a potential way to make it easier. The idea is to develop an AI virtual cell that would ...
A study published in the journal Cell marks the first reported instance of generative AI designing synthetic molecules that can successfully control gene expression in healthy mammalian cells.
Explore how Insilico collaborates with Servier to advance AI-driven drug discovery in oncology for unmet medical needs.
The bigger picture is that generative AI has finally reached a fidelity level where in-silico microscopy can stand in for first-pass experiments. More interesting for biologists, the authors step ...
An AI tool that can analyse abnormalities in the shape and form of blood cells, and with greater accuracy and reliability than human experts, could change the way conditions such as leukaemia are ...
—Researchers in Italy recently evaluated the ability of an artificial intelligence (AI) chatbot to recommend diagnostic and therapeutic approaches to care for patients with renal cell carcinoma (RCC).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback